The Target Big Pharma Couldn't Crack Just Got Its First Drug Filing

In theory, combining both approaches (release the brakes and hit the accelerator) should produce a stronger anti-tumor response. In practice, the field hit a wall.

The first serious attempt was Bristol-Myers Squibb's urelumab, which entered the clinic around 2005. It showed anti-tumor activity, but it also caused serious liver toxicity, including fatal cases. The therapeutic window was impossibly narrow: the doses that worked against cancer were above what patients could safely tolerate.

Pfizer's utomilumab went the other direction. It was much safer, but multiple reviews describe it as simply not potent enough. It couldn't activate the 4-1BB receptor strongly enough to move the needle.

This "Goldilocks problem" (too hot, too cold, never just right) stalled the entire 4-1BB field for years. Later research revealed that the trouble ran deeper than just dosing. The way antibodies physically cluster the 4-1BB receptor and interact with the immune system's Fc pathways turned out to be enormously sensitive. Simple antibody designs kept falling short.

How Opamtistomig Tries to Thread the Needle

Leads Biolabs' approach was to build a bispecific antibody, a molecule engineered to grab two different targets at once. Opamtistomig binds both PD-L1 (the checkpoint target) and 4-1BB (the costimulatory target) simultaneously.

The bispecific design is clever for a specific reason. By linking 4-1BB activation to PD-L1 binding, the drug theoretically concentrates its turbo-boost effect in the tumor microenvironment, where PD-L1 is highly expressed. That means you get the gas pedal where you need it (at the tumor) without flooding the liver with immune activation. It's like giving a sports car GPS-guided acceleration instead of just slamming the pedal everywhere.

Early data offered a glimpse at why regulators took notice. In monotherapy EP-NEC patients at the recommended dose, the drug produced an overall response rate of 33.3%. When combined with chemotherapy, those numbers jumped to a 75% response rate and 92.3% disease control rate. For a cancer with essentially no good options after two lines of chemo, those figures are meaningful.

The Regulatory Runway

The drug has been stacking up regulatory wins. Leads Biolabs secured Breakthrough Therapy Designation from the NMPA back in October 2024. On the U.S. side, the FDA granted Fast Track designation in January 2026 and Orphan Drug designation in November 2024, signaling potential pathways for an American filing down the road.

The company itself isn't a newcomer, either. Founded in 2012, Leads Biolabs went public in Hong Kong (raising roughly $189 million), and it has built a pipeline of 14 drug candidates with six in clinical development. Its deal-making has also turned heads: a 2025 partnership with Dianthus Therapeutics for a different asset (LBL-047) carried a total potential value of up to $1 billion.

Who Else Is in the Race?

Opamtistomig isn't the only PD-L1/4-1BB bispecific in development, but it's clearly out front. BioNTech and Genmab's acasunlimab (GEN1046) is the most visible competitor, though it hasn't reached the NDA stage. Multiple clinical trials across different phases are underway for the PD-L1/4-1BB target pairing, but no one else has a regulatory filing under review.

That lead matters. In a niche indication like EP-NEC, being first to market creates a significant head start, especially in China where the patient population is large and treatment options are limited.

The Bottom Line

For 20 years, 4-1BB was the target that everyone wanted and nobody could tame. Liver toxicity killed the first generation. Weak potency hobbled the second. The bispecific approach may finally be the design that threads the needle between efficacy and safety.

Whether opamtistomig's early-stage numbers hold up under full regulatory scrutiny remains to be seen; the pivotal data package supporting the NDA hasn't been publicly disclosed in detail. But the NMPA accepted the filing and granted priority review, which suggests the data package passed at least the threshold for serious consideration.

If approval comes through in early 2027, Leads Biolabs won't just have a new cancer drug. It'll have cracked open a target that the biggest companies in pharma couldn't figure out. Sometimes the breakthrough doesn't come from the biggest lab. It comes from the one willing to redesign the entire approach.